- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04000009
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
March 31, 2022 updated by: ACADIA Pharmaceuticals Inc.
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
235
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Helsinki, Finland, 00100
- ARTES Psykiatrinen Palvelukeskus Oy (Mederon Ltd.)
-
Kuopio, Finland, 70110
- Savon Psykiatripalvelu Oy
-
Oulu, Finland, 90100
- Oulu Mentalcare Oy
-
Pori, Finland, 28130
- Satakunnan Psykiatripalvelu Oy at Mehiläinen Pori
-
Tampere, Finland, 33200
- Psykiatri- ja psykologikeskus Mentoria
-
-
-
-
-
Belchatow, Poland, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bydgoszcz, Poland, 85-080
- Przychodnia Srodmiescie Sp. z o.o.
-
Gdańsk, Poland, 80-438
- Indywidualna Specijalistyczna Praktyka Lekarska Wiesław Jerzy Cubała
-
Leszno, Poland, 64-100
- Nzop Mentis
-
Szczecin, Poland, 70-480
- Zachodniopomorski Instytut Psychoterapii
-
-
-
-
-
Moscow, Russian Federation, 115522
- Mental Health Research Center, Department #6
-
Saint Petersburg, Russian Federation, 190121
- St. Nicholas the Wonder Worker Psychiatric Hospital
-
Saint Petersburg, Russian Federation, 199004
- City Narcology Hospital
-
Samara, Russian Federation, 443016
- Samara Psychiatric Hospital
-
Saratov, Russian Federation, 410028
- Saratov City Clinical Hospital #2 n.a. V.I. Razumovsky
-
Saratov, Russian Federation, 410060
- Regional Clinical Psychiatric Hospital of St. Sofia
-
St. Petersburg, Russian Federation, 195176
- Psychoneurological Dispensary # 5
-
Voronezh, Russian Federation, 394052
- LION-MED
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Center of Serbia, Clinic for Psychiatry
-
Belgrade, Serbia, 11000
- Clinical Hospital Center Dr Dragisa Misovic
-
Gornja Toponica, Serbia, 18202
- Clinical Centre Nis, Clinic for Psychiatry
-
Kovin, Serbia, 26220
- Special hospital for psychiatric diseases "Kovin
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac , Clinic for Psychiatry
-
Nis, Serbia, 18000
- Centre for Mental Health Protecton, Clinical Center Nis
-
-
-
-
-
Kosice, Slovakia, 04017
- EPAMED s r.o.
-
Liptovsky Mikulas, Slovakia, 03123
- Liptovska nemocnice s poliklinikou MUDr. Ivana Stodolu, Psychiatricke oddelenie
-
Svidnik, Slovakia, 50474
- Centrum Zdravia R.B.K., s.r.o.
-
-
-
-
-
Durbanville,, South Africa, 7550
- Flexivest Fourteen Research Centre, Unit 1, Durbanville Health Center
-
-
-
-
-
Dnipro, Ukraine, 49005
- Regional Centre of Psychosomatic Disorders based on Psychoneurology Department, Communal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnykov
-
Kharkiv, Ukraine, 61091
- Institute of neurology, Psychiatry and Narcology of NAMS of Ukraine, MC "Neuron"
-
Kyiv, Ukraine, 01030
- Kyiv Railway Clinical Hospital № 1 of Branch "Health Center" of the Public joint stock company "Ukrainian Railway"
-
Stepanivka, Ukraine, 73488
- Kherson Regional Psychiatric Hospital Department # 3 and # 10 Kherson region,
-
Ternopil, Ukraine, 46027
- Ternopil Regional Communal Clinical Psychoneurological Hospital, psychiatric department # 2 (men), psychiatric department # 6 (women), Ternopil State Medical University n.a. I.Y. Gorbachevskyy, Chair of Psychiatry, Narcology and Medical Psychology
-
Vinnytsya, Ukraine, 21005
- Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I.Yushchenko", Male Department #14, Female Department #15, Vinnytsya National Medical University n.a. M.I.Pyrogov, Department of Psychiatry, Narcology and Psychotherapeutic
-
-
-
-
-
Blackpool, United Kingdom, FY2 0JH
- MAC Clinical Research- Blackpool
-
Liverpool, United Kingdom, L34 1BH
- MAC Clinical Research Ltd.-Liverpool
-
Manchester, United Kingdom, M13 9NQ
- MAC Clinical Research- Manchester
-
-
-
-
California
-
Garden Grove, California, United States, 90806
- CNS Network
-
Glendale, California, United States, 91206
- Behavioral Research Specialists
-
Irvine, California, United States, 92614
- Irvine Clinical Research
-
Lemon Grove, California, United States, 91945
- Synergy San Diego
-
Oakland, California, United States, 94607
- Pacific Research Partners, LLC
-
Orange, California, United States, 92868
- NRC Research Institute
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80910
- MCB Clinical Research Centers, LLC
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Clinical Neuroscience Solutions ( CNS Healthcare)-Jacksonville
-
Maitland, Florida, United States, 32751
- Meridien Research
-
Miami, Florida, United States, 33174
- Florida Research Center, Inc.
-
Orlando, Florida, United States, 32801
- CNS Health Care (Orlando)
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
Atlanta, Georgia, United States, 30328
- Synexus Clinical Research
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Great Lakes Clinical Trials
-
Libertyville, Illinois, United States, 60048
- Capstone Clinical Research
-
-
Kansas
-
Prairie Village, Kansas, United States, 66208
- Collective Medical Research, LLC
-
-
Massachusetts
-
Watertown, Massachusetts, United States, 02472
- Adams Clinical
-
-
New York
-
Brooklyn, New York, United States, 11229
- Integrative Clinical Trials
-
Brooklyn, New York, United States, 11235
- Social Psychiatry Research Institute (SPRI)
-
New York, New York, United States, 10128
- The Medical Research Network, LLC
-
New York, New York, United States, 10029
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai
-
Rochester, New York, United States, 14618
- Finger Lakes Clinical Research
-
-
Ohio
-
Garfield Heights, Ohio, United States, 44125
- Charak Clinical Research Center
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Research Network (Oregon) Inc.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 26464
- Coastal Carolina Research Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Research Strategies of Memphis, LLC
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions CNS Healthcare
-
-
Texas
-
Dallas, Texas, United States, 75231
- Future Search Trials of Dallas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas, Inc.
-
Wichita Falls, Texas, United States, 76309
- Grayline Research Center
-
-
Wisconsin
-
Waukesha, Wisconsin, United States, 53188
- IPC Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Completed the antecedent study, Study ACP-103-054 or Study ACP-103-059
- May benefit from longer term therapy with open-label pimavanserin treatment
- If the subject is female, she must not be pregnant or breastfeeding. She must also be of nonchildbearing potential OR must agree to use acceptable methods of contraception
Exclusion Criteria:
- Is determined to be inappropriate for the study
- Has developed neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical or mental disorder, including cancer or malignancies that would affect the patient's ability to participate in the program
Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug - pimavanserin
Pimavanserin 34 mg tablets
|
Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-emergent Adverse Events (TEAEs)
Time Frame: 52 weeks
|
Number of patients with treatment emergent AEs
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 6, 2019
Primary Completion (Actual)
February 22, 2021
Study Completion (Actual)
February 22, 2021
Study Registration Dates
First Submitted
June 25, 2019
First Submitted That Met QC Criteria
June 25, 2019
First Posted (Actual)
June 27, 2019
Study Record Updates
Last Update Posted (Actual)
April 5, 2022
Last Update Submitted That Met QC Criteria
March 31, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pimavanserin
Other Study ID Numbers
- ACP-103-055
- 2018-003252-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adjunctive Treatment of Major Depressive Disorder
-
ACADIA Pharmaceuticals Inc.CompletedAdjunctive Treatment of Major Depressive DisorderUnited States
-
Clexio Biosciences Ltd.CompletedAdjunctive Treatment of Major Depressive DisorderUnited States, Puerto Rico
-
ACADIA Pharmaceuticals Inc.CompletedAdjunctive Treatment of Major Depressive DisorderUnited States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
-
Wayne Goodman MDActive, not recruitingTreatment Resistant Major Depressive DisorderUnited States
-
Baylor College of MedicineIcahn School of Medicine at Mount SinaiCompletedMajor Depressive Disorder (MDD) | Treatment Resistant Depression (TRD)United States
-
Helse Stavanger HFWithdrawnMajor Depressive Disorder | Treatment Resistant Depression | Major Depressive Episode
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
University of MinnesotaCompleted
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, Canada
-
Mclean HospitalRecruitingMajor Depressive DisorderUnited States
Clinical Trials on Pimavanserin
-
ACADIA Pharmaceuticals Inc.CompletedDementia-related PsychosisUnited States, Spain, Poland, Ukraine, Chile, Czechia, United Kingdom, Bulgaria, France, Germany, Italy, Serbia, Slovakia
-
ACADIA Pharmaceuticals Inc.TerminatedAgitation and Aggression in Alzheimer's DiseaseUnited States, France, Spain, Chile, United Kingdom
-
ACADIA Pharmaceuticals Inc.Approved for marketingParkinson's Disease Psychosis
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisSpain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
-
VA Office of Research and DevelopmentACADIA Pharmaceuticals Inc.RecruitingInsomnia | Post-traumatic Stress DisorderUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States, Austria, France, Canada, Belgium, Russian Federation, Serbia, Ukraine, Poland, Portugal, Italy, India, United Kingdom, Sweden
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisUnited States, Canada
-
Ohio State UniversityACADIA Pharmaceuticals Inc.Not yet recruiting
-
Bjorn H. EbdrupRigshospitalet, Denmark; ACADIA Pharmaceuticals Inc.; GCP unit, Copenhagen University...WithdrawnSchizophrenia | Psychosis